- Home
- DBD vs NAMS Comparison
DBD vs NAMS Comparison
Compare DBD & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | NAMS |
|---|---|---|
| Founded | 1859 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | DBD | NAMS |
|---|---|---|
| Price | $85.93 | $29.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $90.00 | $46.75 |
| AVG Volume (30 Days) | 622.1K | ★ 803.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $3,805,700,000.00 | N/A |
| Revenue This Year | $3.56 | $17.96 |
| Revenue Next Year | $3.25 | $540.65 |
| P/E Ratio | $33.26 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $43.00 | $16.79 |
| 52 Week High | $89.05 | $42.00 |
Technical Indicators
Market Signals| Indicator | DBD | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 38.54 |
| Support Level | $68.51 | $23.48 |
| Resistance Level | N/A | $37.25 |
| Average True Range (ATR) | 2.93 | 1.72 |
| MACD | 0.04 | -0.45 |
| Stochastic Oscillator | 73.44 | 3.04 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.